** Cancer drug developer CEL-SCI's CVM.A shares plunge 19.5% to $10.50 in extended trading

** CVM unveils proposed public offering of stock and pre-funded warrants; size not disclosed

** Proceeds from offering will be used to fund continued development of Multikine - its treatment for head and neck cancer - and other purposes

** ThinkEquity acting as sole placement agent for the offering

** CVM has 6.9 million outstanding shares for $89.7 million market cap, per LSEG data

** As of last close, CVM stock up 8.7% YTD

(Reporting by Arasu Kannagi Basil in Bengaluru)

((ArasuKannagi.Basil@thomsonreuters.com))